Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AJP001
- Development stage
- Preclinical
- Lead developer
- FunPep
- Modality
- Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
AJP001 is a proprietary carrier peptide and adjuvant developed by FunPep, serving as a core component of the company's STEP UP (Search Technology for Functional Peptides) platform. It is designed to be conjugated with target peptide antigens to overcome the typically low immunogenicity of short peptides. AJP001 functions by facilitating the delivery of the antigen and providing adjuvant activity that stimulates the production of high-titer antibodies against the target protein. Rather than being a standalone therapeutic, AJP001 is a platform technology component integrated into various peptide vaccines in FunPep's pipeline, such as FPP003 (targeting IL-17A) and FPP004 (targeting IgE).
- Other names
- STEP UP carrier peptideFunPep adjuvant peptide
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on AJP001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AJP001.